Biotech Values

[mcbio]

ACOR is surprisingly undervalued!

ACOR projects revenue for FY2014 of $345-$350 Million.

finance.yahoo.com/news/acorda-therapeutics-reports-third-quarter-100000894.html

It has two drugs in phase 3:
Dalfampridine for the treatment of post-stroke walking deficits which produces promising data. See company PR: finance.yahoo.com/news/acorda-announces-initiation-phase-3-120100435.html
CVT-301 for the treatment of OFF episodes in Parkinson’s disease (acquisition of Civitas Therapeutics).

However, the MC is just $1.7B. Based on the revenue of $350M/yr, the MC is supposed to be between $2.5B - $3.5B or $60 to $80 per share.

Does anyone have any comments why the MC is too low?

I think all of that large revenue is tied to Ampyra and I think there are some generic fears if memory serves?